Replies to post #112979 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

Please, Substantiate Anavex 2-73 Results Worse Than Existing

Once again, to get FDA approval, Anavex 2-73 must show that its efficacy (symptom suppression) is at least as good as any drug on the market, and also that it has fewer side effects.

Show us, please, just how the existing drugs surpass Anavex 2-73.

In the Australian study, cognition was either maintained or improved over the period of time.

With current drugs, cognition is maintained only for short periods of time, ultimately with reversion to lethal progression. Every one of these drugs state emphatically that favorable treatment results are only for a period of time, with universal resumption of disease progression.

Can you show us an on-the-market Alzheimer's drug (approval competition) that matches or beats the symptom suppression profile of Anavex 2-73?

Can you show us a current Alzheimer's drug with a superior side effects profile?

Exact names of the drugs are requested.

Of course, in the absence of any of these, you will state that the Australian trial data are either incomplete or bogus.

Those of us holding our AVXL positions are confident the upcoming Phase 3 trial data will confirm the Australian data, and FDA approval will be forthcoming.

Those with alternative perspectives, respectfully, should not buy or own a single share of AVXL.

A matter of one's due diligence, of course.